miR-744 is a potential prognostic marker in patients with hepatocellular carcinoma

Clinics and Research in Hepatology and Gastroenterology

Volumn 39, Issue 3, 2015, Pages 359-365

  Tan, Yu Le ^a   Bai, Zhi Gang ^a   Zou, Wei Long ^b   Ma, Xue Mei ^a   Wang, Ting Ting ^a   Guo, Wei ^a   Liu, Jun ^a   Li, Jiang She ^a   Jie Yin, ^a   Zang, Yun Jin ^b   Zhang, Zhong Tao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 744; TUMOR MARKER; UNCLASSIFIED DRUG; MIRN744 MICRORNA, HUMAN;

AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CANCER TISSUE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INDEPENDENT VARIABLE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; OVERALL SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION; TUMOR INVASION; VERY ELDERLY; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; METABOLISM; MIDDLE AGED; PROGNOSIS;

CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS;

EID: 84937194216     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2014.09.010     Document Type: Article

References (35)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Bosch F.X., Ribes J., Diaz M., Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127:S5-S16.
3. Malek N.P., Schmidt S., Huber P., et al. The diagnosis and treatment of hepatocellular carcinoma. Dtsch Arztebl Int 2014, 111:101-106.
4. ACS What are the key statistics about liver cancer. In Edition 2012.
5. Imamura H., Matsuyama Y., Tanaka E., et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003, 38:200-207.
6. Strong R.W. Transplantation for liver and biliary cancer. Semin Surg Oncol 2000, 19:189-199.
7. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
8. Wang J., Sen S. MicroRNA functional network in pancreatic cancer: from biology to biomarkers of disease. J Biosci 2011, 36:481-491.
9. Xu L., Beckebaum S., Iacob S., et al. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J Hepatol 2014, 60:590-598.
10. Giray B.G., Emekdas G., Tezcan S., et al. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma. Mol Biol Rep 2014, 41(7):4513-4519.
11. Wu G.G., Li W.H., He W.G., et al. Mir-184 post-transcriptionally regulates SOX7 expression and promotes cell proliferation in human hepatocellular carcinoma. PLoS One 2014, 9:e88766-e88879.
12. Leivonen S.-K., Sahlberg K.K., Mäkelä R., et al. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Mol Oncol 2014, 8:93-104.
13. Martin J., Jenkins R.H., Bennagi R., et al. Post-transcriptional regulation of transforming growth factor beta-1 by microRNA-744. PLoS One 2011, 6:e25044.
14. Vislovukh A., Kratassiouk G., Porto E., et al. Proto-oncogenic isoform A2 of eukaryotic translation elongation factor eEF1 is a target of miR-663 and miR-744. Br J Cancer 2013, 108:2304-2311.
15. Huang V., Place R.F., Portnoy V., et al. Upregulation of cyclin B1 by miRNA and its implications in cancer. Nucleic Acids Res 2012, 40:1695-1707.
16. Lin F., Ding R., Zheng S., et al. Decrease expression of microRNA-744 promotes cell proliferation by targeting c-Myc in human hepatocellular carcinoma. Cancer Cell Int 2014, 14:58.
17. Mazzaferro V., Llovet J.M., Miceli R., et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009, 10:35-43.
18. Varkonyi-Gasic E., Hellens R.P. Quantitative stem-loop RT-PCR for detection of microRNAs. Methods Mol Biol 2011, 744:145-157.
19. D'Amico F., Schwartz M., Vitale A., et al. Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl 2009, 15:1278-1287.
20. Volk M.L., Vijan S., Marrero J.A. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant 2008, 8:839-846.
21. Prasad K.R., Young R.S., Burra P., et al. Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver Transpl 2011, 17(Suppl.2):S81-S89.
22. Ravaioli M., Grazi G.L., Piscaglia F., et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008, 8:2547-2557.
23. Cillo U., Vitale A., Bassanello M., et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 2004, 239:150-159.
24. Klintmalm G.B. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg 1998, 228:479-490.
25. Brockhausen J., Tay S.S., Grzelak C.A., et al. miR-181a mediates TGF-β-induced hepatocyte EMT and is dysregulated in cirrhosis and hepatocellular cancer. Liver Int 2014, [Epub ahead of print]. 10.1111/liv.12517.
26. Shibuya H., Iinuma H., Shimada R., et al. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology 2010, 79:313-320.
27. Bloomston M., Frankel W.L., Petrocca F., et al. MIcrorna expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007, 297:1901-1908.
28. Iorio M.V., Ferracin M., Liu C.G., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65:7065-7070.
29. Budhu A., Jia H.L., Forgues M., et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008, 47:897-907.
30. Toso C., Mentha G., Majno P. Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence. Am J Transplant 2011, 11:2031-2035.
31. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866.
32. Landgraf P., Sheridan R.M.R. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007, 129(7):1401-1414.
33. Köberle V., Kronenberger B., Pleli T., et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer 2013, 49:3442-3449.
34. Song M.Y., Pan K.F., Su H.J., et al. Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. PLoS One 2012, 7:14.
35. Kubiczkova L., Slaby K.F.O. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica 2014, 99(3):511-518.